Celldex Therapeutics, Inc. — Director's Dealing 2019

Jul 9, 2019

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Celldex Therapeutics, Inc. (CLDX)
CIK: 0000744218
Period of Report: 2019-07-08

Reporting Person: Young Diane C. (SVP, Chief Medical Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2019-07-08	Incentive Stock Option (right to buy)	$2.71	A	60000	Acquired	2029-07-08	Common Stock (60000)	Direct

Footnotes

F1: Represents option granted by Issuer pursuant to its 2008 Stock Option and Incentive Plan.

F2: 25% vests on July 8, 2020 and the remainder vests quarterly (in equal amounts) over the subsequent 12 quarters.